American Diabetes Association

Explore groundbreaking findings from the REDEFINE trials on CagriSema's impact on weight loss and diabetes management at ADA 2025.

Philis-Tsimikas shared the latest findings demonstrating inferiority after switching from daily basal insulin to weekly insulin efsitora.

Kevin Sayer joins the program to discuss the latest from Dexcom and preview where the business is headed in an evolving diabetes landscape.

A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes.

Steger discussed findings from a 6-month lifestyle investigating TRE+ER and IER.

A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.

CagriSema shows weight loss results in recent trials comparable to existing interventions.

Xue discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention.

A phase 3 trial reveals ecnoglutide significantly reduces body weight in overweight patients, showcasing its potential as a novel obesity treatment.

New findings reveal semaglutide significantly enhances walking ability and quality of life for patients with T2D and PAD.

A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.

Automated insulin delivery systems enhance blood glucose control for pregnant women with type 1 diabetes, potentially advancing diabetes care.

Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.

The ACHIEVE-1 trial reveals orforglipron's potential as a breakthrough treatment for type 2 diabetes.

New research reveals amycretin's promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.

Most participants (83%) did not require exogenous insulin 1 year after zimislecel (VX-880) infusion.

New ADA guidelines enhance obesity care, focusing on personalized treatment, bias reduction, and inclusive practices to improve patient outcomes.

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

In this special episode, cohosts preview the most anticipated data and explore clinical implications in diabetes and obesity.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 updates from the 84th American Diabetes Association (ADA) Scientific Sessions.

In this episode, hosts recaps their picks for top diabetes technology-related updates from ADA 2024, including news from Omnipod, MiniMed 780G, and the Tandem mobi.

Carol Levy, MD, discusses INHALE-3 trial and how to incorporate individual patient-level factors into the management of patients with type 1 diabetes who could benefit from inhaled insulin.

Monica Gomberg, MD, joins the podcast to discuss how Blue Circle Health leverages free support and education programs to improve management and quality of life in people with types 1 diabetes.

Davida Kruger, NP, joins the podcast to discuss updates in automated insulin delivery and continuous glucose monitoring systems from ADA 2024.

Data on outcomes stratified according to baseline use of SGLT2 inhibitors from the FLOW trial were presented at ADA 2024.

Ralph DeFronzo, MD, discusses the results of the first phase of the CATALYST trial and how results should influence the care of patients with difficult-to-treat type 2 diabetes.

The CATALYST trial sheds light on the true prevalence of hypercortisolism among difficult-to-control type 2 diabetes, with data at ADA 2024 shedding light on adrenal abnormalities and presence among subgroups.

Findings highlight the potential utility of low-dose SGLT2 inhibitors for optimizing diabetes control and managing renal complications in pediatric patients with type 1 diabetes.

Study results highlight the impact of continuous glucose monitoring on glucose control and HbA1c improvements in patients with type 2 diabetes, regardless of treatment regimen.

Teva Pharmaceuticals’ launch of an authorized generic of liraglutide injection 1.8 mg (Victoza) for type 2 diabetes makes it the first-ever generic GLP-1.